// App-Quantinova.ai

P516 : Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study

Researchers

Presenter

  • Karki, C

Principal Investigators

  • Athavale, A

  • Hantsbarger, G

  • Lee, K

  • Milicevic, S

  • Perovic, M

  • Raven, L

  • Sajak-Szczerba, M

  • Abilash, V

  • Tozer, P

Medical Centers

  • Takeda Pharmaceuticals USA- Inc., Global Evidence and Outcomes, Cambridge MA, United States

  • Trinity Partners- LLC., Insights & Analytics, Waltham- MA, United States

  • Takeda Pharmaceuticals USA Inc., Safety and Health Value Statistics, Cambridge- MA, United States

  • Crohn's and Colitis Canada, Research & Patient Programs, Toronto, Canada

  • Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland

  • European Federation of Crohn’s and Ulcerative Colitis Associations, European Federation of Crohn’s and Ulcerative Colitis Associations, Brussels, Belgium

  • Crohn's and Colitis Australia, n/a, Camberwell, Australia

  • an Federation of Crohns and Ulcerative Colitis Associations, Medical Writing, Brussels, Belgium

  • St Mark’s Hospital and Academic Institute, Fistula Research Unit, London, United Kingdom

Locations

  • United States

  • Canada

  • Switzerland

  • Belgium

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • 3β-hydroxysterol Δ24-reductase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cross-Sectional

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved